Ph.D., Columbia University, 1983
My lab is applying genome-wide “big-picture” methods to the study of cancer. This means we investigate both genetic alternations that promote cancer, as well as factors in the tumor environment that affect cancer proliferation and tumor response to anticancer therapeutics. We have performed integrative functional studies that have revealed oncogenic mechanisms in breast, liver, colon and lung cancers.
Scott Powers’ work focuses on gene alterations that cause cancer and factors that influence responses to specific anticancer drugs. His lab uses technologies that probe the entire genome to identify candidate cancer genes and evaluate their functional role in cell transformation and tumor biology. They also use whole-genome technologies to guide development of novel cancer diagnostics and therapeutics. Using DNA copy number analysis, the Powers group pinpoints novel amplified oncogenes and then applies functional studies to address the mechanisms by which they are implicated in oncogenesis. They have successfully applied this approach in breast, liver, colon, and lung cancers. Powers has also had an important role in the development of a distinctive CSHL approach to functional study of cancer genes. Called integrative oncogenomics, it is a rapid, large-scale screen for genes that are deleted or amplified in human cancers and suspected of being tumor suppressors, in the case of deletions, or oncogenes, in the case of amplifications.
Chen, M. and Nowak, D. G. and Narula, N. and Robinson, B. and Watrud, K. and Ambrico, A. and Herzka, T. M. and Zeeman, M. E. and Minderer, M. and Zheng, W. and Ebbesen, S. H. and Plafker, K. S. and Stahlhut, C. and Wang, V. M. and Wills, L. and Nasar, A. and Castillo-Martin, M. and Cordon-Cardo, C. and Wilkinson, J. E. and Powers, S. and Sordella, R. and Altorki, N. K. and Mittal, V. and Stiles, B. M. and Plafker, S. M. and Trotman, L. C. (2017) The nuclear transport receptor Importin-11 is a tumor suppressor that maintains PTEN protein. J Cell Biol
Li, J. and Sordella, R. and Powers, S. (2016) Effectors and potential targets selectively upregulated in human KRAS-mutant lung adenocarcinomas. Sci Rep 6pp. 27891.
Powers, S. and Pollack, R. E. (2016) Inducing stable reversion to achieve cancer control. Nature Reviews Cancer 16(4) pp. 266-270.
Wang, X. and Yu, X. and Zhu, W. and McCombie, W. R. and Antoniou, E. and Powers, R. S. and Davidson, N. O. and Li, E. and Williams, J. (2015) A trimming-and-retrieving alignment scheme for reduced representation bisulfite sequencing. Bioinformatics 31(12) pp. 2040-2042.
Li, J. and Chanrion, M. and Sawey, E. and Wang, T. and Chow, E. and Tward, A. and Su, Y. and Xue, W. and Lucito, R. and Zender, L. and Lowe, S. W. and Bishop, J. M. and Powers, S. (2015) Reciprocal Interaction of Wnt and RXR-alpha Pathways in Hepatocyte Development and Hepatocellular Carcinoma. PLoS One 10(3) pp. e0118480.Additional materials of the author at
CSHL Institutional Repository